Rees promoted to head of BBI Holdings
This article was originally published in Clinica
Lyn Rees has been promoted CEO of medtech and diagnostics group BBI Holdings. Mr Rees first joined BBI over 10 years ago as sales and marketing manager of the group's diagnostics division, BBInternational; his most recent role was CEO of that business. In between, he was responsible for setting up BBI Healthcare, which focuses on commercialising the company's novel diabetes care products. As group CEO, Mr Rees will oversee BBInternational, BBI Healthcare, as well as the group's enzyme purification and extraction business, BBI Enzymes.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.